ProCE Banner Activity

Questions and Answers From the ENDO 2023 Symposium: Addressing Treatment Challenges in Growth Hormone Deficiency With Novel Long-Acting Therapies

Clinical Thought

Dr. Laurence Katznelson reviews some questions and answers from the ENDO 2023 session on the treatment challenges in growth hormone deficiency. Read this commentary to understand more about the available and emerging treatment options in pediatric and adult patients and get insights into overcoming challenges with long-term GHD management.

Released: July 11, 2023

Expiration: July 11, 2024

Share

Faculty

Laurence Katznelson

Laurence Katznelson, MD

Professor of Medicine (Endocrinology) and Neurosurgery
Associate Dean of Graduate Medical Education
Medical Director, Pituitary Center
Stanford Health Care, Stanford School of Medicine
Stanford, California

Provided by

Jointly provided by Clinical Care Options, LLC and Endocrine Society

ProCE Banner
ProCE Banner

Supporters

This activity is supported by an educational grant from Novo Nordisk.

Novo Nordisk

Faculty Disclosure

Primary Author

Laurence Katznelson, MD

Professor of Medicine (Endocrinology) and Neurosurgery
Associate Dean of Graduate Medical Education
Medical Director, Pituitary Center
Stanford Health Care, Stanford School of Medicine
Stanford, California

Laurence Katznelson, MD: consultant/advisor/speaker: Novo Nordisk, Recordati, Pfizer, Stonebridge; researcher: Camarus, Novartis.